RESEARCH PEPTIDE FUNDAMENTALS / FAQ
Questions About These Four Peptides
Direct, citation-anchored answers to the questions readers most often ask about BPC-157, GHK-Cu, KPV, and semaglutide.
What does BPC-157 do in the body?
In animal studies, BPC-157 is linked to faster healing of tendons, ligaments, and the stomach lining, largely through promoting new blood-vessel growth (angiogenesis) via the VEGFR2 pathway [4]. It has also been shown to accelerate healing of a fully transected rat Achilles tendon [6] and to reduce gastric ulcer size in rats [5]. Almost all of this evidence comes from animal models; a 2025 human pilot found intravenous BPC-157 well tolerated in two adults, but that study measured safety, not effectiveness [1].
Is BPC-157 a growth hormone?
No. BPC-157 is not a growth hormone and does not directly supply growth hormone to the body. It has been shown in lab studies to sensitize the growth-hormone receptor in tendon fibroblasts, tendon-building cells, meaning it may make those cells more responsive to growth hormone that's already present — a different thing from being a growth hormone itself. This finding is preclinical, at the cell-culture level [6].
Does BPC-157 work immediately?
The published research doesn't describe an 'immediate' effect. Animal studies measure healing over days to weeks; for example, accelerated Achilles tendon healing was assessed across the course of tendon repair, not within hours [6]. In research-use communities, some people report noticing changes in stiffness or pain within one to three weeks, but these are personal anecdotal reports, not measurements from a controlled study, and no clinical trial has established a timeline for any effect in humans.
Does BPC-157 damage the liver?
The only human data available, a 2025 pilot study of intravenous BPC-157 up to 20 mg in two adults, found no measurable changes in liver (hepatic) biomarkers, alongside no changes in cardiac, kidney, thyroid, or glucose markers [1]. That is a single tiny study, not a liver-safety trial, and a 2025 review notes the overall human evidence for BPC-157 is extremely limited, with rigorous large-scale safety trials still lacking [2]. No conclusion about liver safety can be drawn from research this limited.
What does a GHK-Cu peptide do?
GHK-Cu is a copper-binding tripeptide best studied as a topical ingredient that stimulates skin cells (fibroblasts) to produce more collagen, elastin, and other structural proteins, while its bound copper ion helps cross-link those fibers and provides antioxidant activity [11]. A 2025 review reported that topical GHK-Cu increased procollagen synthesis in 70% of treated subjects, compared with 50% for vitamin C and 40% for retinoic acid, in the studies reviewed [8].
What is GHK-Cu and how does it work?
GHK-Cu is the tripeptide glycyl-histidyl-lysine (Gly-His-Lys) bound to a copper(II) ion. It works by acting as both a copper-delivery molecule and a direct signal to skin cells: at low concentrations it stimulates fibroblasts to build more collagen and elastin, rebalances the enzymes that break matrix proteins down, and, via its bound copper, supports the cross-linking enzyme lysyl oxidase and provides antioxidant activity. Gene-expression analysis found it alters activity of roughly 31% of human genes at a meaningful threshold, with the strongest effects on wound-repair and antioxidant programs [9].
Is GHK-Cu peptide really anti-aging?
In its topical, cosmetic form, GHK-Cu has real controlled human evidence behind specific anti-aging-adjacent claims — increased collagen synthesis versus vitamin C and retinoic acid in comparative studies [8], and a 45-person hair-growth trial showing a significant increase in hair count for a GHK-containing combination product versus placebo [10]. Broader 'anti-aging' marketing claims, however, often extrapolate well beyond what's been directly tested, and a large share of the foundational gene-expression research comes from a single research group, which limits independent replication.
What is the difference between GHK and GHK-Cu?
GHK is the plain three-amino-acid peptide (glycine-histidine-lysine) on its own. GHK-Cu is that same peptide chemically bound to a copper(II) ion. The distinction matters because much of GHK-Cu's documented tissue-remodeling activity depends on the copper being properly bound — the free GHK peptide without copper does not reproduce key effects, such as stimulating a specific matrix-remodeling enzyme (MMP-2), in cell studies. Products where the copper isn't intact may not behave the way the copper-bound research describes.
What is KPV peptide?
KPV is a three-amino-acid peptide (lysine-proline-valine) that corresponds exactly to the tail end (residues 11-13) of alpha-melanocyte-stimulating hormone (alpha-MSH), a larger natural hormone. It's studied for its anti-inflammatory activity, which it retains from the parent hormone even though it lacks alpha-MSH's pigment-affecting action [17]. As of this writing, no published human clinical trials of KPV exist — the entire evidence base is cell-culture and animal research.
What does KPV peptide do?
In lab and mouse studies, KPV reduces inflammation by suppressing two inflammatory signaling pathways (NF-kB and MAP-kinase) and lowering production of inflammatory cytokines [15]. In the gut specifically, it's taken up directly into intestinal cells via a transporter called PepT1, which is more active in inflamed tissue, and orally administered KPV reduced colitis severity in multiple mouse models [15][16]. All of this evidence is preclinical; there are no human studies of what KPV does in people.
What is KPV peptide used for?
In research settings, KPV is studied almost exclusively for inflammatory bowel disease (colitis) in mouse models, including newer nanoparticle-delivery formulations designed to target it directly to inflamed gut tissue [13][14]. It is not an approved treatment for any human condition, has no established human dose, and is sold only as a laboratory research chemical.
What is KPV peptide good for?
Based on the published animal and cell-culture research, KPV shows anti-inflammatory activity across several models, reducing colitis severity in mice [15][16], and, per a broader review of related tripeptides, showing protective effects across other inflammatory animal models including dermatitis, arthritis, and airway inflammation [17]. 'Good for' claims beyond this preclinical evidence, for human gut health, skin, or general anti-inflammatory use, are not supported by any published human data.
What is semaglutide?
Semaglutide is a 31-amino-acid synthetic peptide engineered to mimic and outlast the natural hormone GLP-1 (glucagon-like peptide-1). It is FDA-approved for type 2 diabetes, chronic weight management, reducing cardiovascular events in adults with established cardiovascular disease and overweight or obesity, and, since 2025, a liver condition called MASH. It is available as a once-weekly injection and a once-daily oral tablet, and, unlike the other three peptides on this site, it is a prescription medicine, not a research chemical [22].
What is semaglutide used for?
FDA-approved uses include lowering blood sugar in type 2 diabetes, reducing body weight in chronic weight management, reducing the risk of major cardiovascular events in adults with established cardiovascular disease and overweight or obesity, and treating MASH. In a dedicated kidney-outcomes trial, it also reduced major kidney-disease events by 24% in people with type 2 diabetes and chronic kidney disease [19][20].
How does semaglutide work?
Semaglutide activates GLP-1 receptors throughout the body. In the pancreas, it boosts insulin release specifically when blood sugar is elevated and suppresses glucagon, a hormone that raises blood sugar. It also slows gastric emptying, which blunts post-meal blood-sugar spikes. Its structural design, a modified amino acid that blocks the enzyme DPP-4 plus a fatty side-chain that binds albumin, is what lets it stay active in the bloodstream for about a week instead of the roughly two minutes natural GLP-1 lasts.
How does semaglutide work for weight loss?
Semaglutide's weight effect is thought to be mostly central, it reaches appetite-control circuits in the hypothalamus and brainstem, activating neurons that signal fullness and suppressing neurons that drive hunger, which reduces both how much people eat and, per patient reports, the mental preoccupation with food. In the STEP 1 trial, this produced an average -14.9% body-weight change at 68 weeks versus -2.4% with placebo [21]. In the head-to-head SURMOUNT-5 trial, semaglutide was outperformed by tirzepatide (-13.7% versus -20.2%), showing this mechanism, while effective, isn't the strongest available in its class [18].